In order to expand its present earning condition by its products and aiming to add up several Cardiovascular tools, Cardinal Health Inc. (NYSE:CAH) is planning to obtain Johnson & Johnson’s (NYSE:JNJ) Cordis as broadcasted yesterday, by specializing in deployment of their medical equipment and pharmaceuticals with the agreement of $1.94 billion.

Cardinal Health Inc. (NYSE:CAH) has made use of a chance in time and has taken a step to win the world wide creators of endovascular and cardiology tools for instance catheters, stents, and many other surgical devices. This was done so that the company, dealing with cardiac related devices, can have a strong position in market. Abbott Laboratories, Boston Scientific Corporation and Medtronic PLC being the greatest competitors are the major targets of Cardinal Health Inc. (NYSE:CAH).

Due to the planned agreement, the Ohio based company would get a better platform to bargain against the hospitals and medical centers that have arranged great discounts by ceasing arguments made by companies with one another and the insurers. Through this, Cardinal Health Inc. (NYSE:CAH) would show prominent increments in its sales at a high rate.

The medical segment head of Cardinal Health Inc. (NYSE:CAH) attended a press release the day before, and reported that the increase of these schemes will push them to become a necessity for hospitals.

Sales of almost $780 million for 12 months of the past year were produced by Cordis in the capital of Ohio. The earned amount was distributed between endovascular and cardiology products. More than 70% of sales around the world have been gathered by the unit from above 50 countries incorporating Brazil, UK, Italy, China, Germany, Japan and France. Cardinal Health Inc. (NYSE:CAH) is well-established and capable of development movements for Cordis. According to the survey, the company had more than $90 billion sales for the full fiscal year 2014.

On the plan of the procurement of Cordis, the Chairman and CEO of Cardinal Health Inc. (NYSE:CAH), George Barrett, gave his point of view yesterday that they were truly thrilled about the plan of acquiring Cordis. He further stated that Cordis will prove to be an outstanding step forward in the cardiovascular scheme as it has a high heritage in the revolution of cardiovascular field. It is going to prove to be a conspicuous agreement deal and they hope to cope with the master plan in health care systems by alteration of doctor’s preference devices and other items.

Cardinal Health Inc. (NYSE:CAH) has made a judgment about its future that would increase the earnings of $0.2 per share with the consequence of notable synergies of above $100 million for every year from late fiscal year 2018.

Johnson & Johnson’s (NYSE:JNJ) is looking into the growth of its high-selling business with narrowing its portfolio, so the acquisition would benefit Johnson & Johnson’s (NYSE:JNJ) as well. The plan of Cardinal Health Inc. (NYSE:CAH) to get the aimed $1 billion price-decrease each year lies parallel to Cordis.

Johnson & Johnson (NYSE:JNJ) is demanding $5 billion in damages and interest from Boston Scientific (NYSE:BSX). Boston Scientific (NYSE:BSX) has a strong market reputation with a market capitalization, as of Tuesday of 17.8 billion. Moving against Boston Scientific (NYSE:BSX) could prove costly for Johnson & Johnson (NYSE:JNJ).

The trial will be a two part trial that will go on till December. Both parties have brought in well-known lawyers to handle the case which signifies how much important it is to both companies. It’s a matter of reputation for both the companies, more so for Boston Scientific (NYSE:BSX) because there are 5 billion on the line and neither of these companies is willing to back down or settle it out of court.

The background of the case is that Johnson & Johnson (NYSE:JNJ) entered a deal with Guidant back in 2004 to make cardiovascular devices. The price was set at a whopping 21.5 billion and to cater to antitrust concerns, Johnson & Johnson (NYSE:JNJ) and Guidant agreed upon the fact that the former would sell a portion of Guidant’s business to Abbot Laboratories. The deal also had a clause which prohibited the company from dealing with other companies.

Boston Scientific (NYSE:BSX) made a 25 billion offer to Guidant and also agreed to pay assets to Abbot Laboratories. When Johnson & Johnson (NYSE:JNJ) came to know that Guidant was dealing with another company, it sued Guidant and Abbot back in 2006 for breach of contract. Boston Scientific (NYSE:BSX) later on bought Guidant for 27 billion and paid 705 million termination fees to Johnson & Johnson (NYSE:JNJ).

Boston Scientific (NYSE:BSX) also pressed that Guidant didn’t knowingly breach the contract but Johnson & Johnson (NYSE:JNJ) since then has not backed down from the fiasco. It is adamant on taking Boston Scientific (NYSE:BSX) to the court and shakes the money out of them, the money which they could have made with Guidant back in 2004.

Analysts claim that there is a lot to lose for both the companies although Boston Scientific (NYSE:BSX) has gotten itself in a spot where it will have to pay Johnson & Johnson (NYSE:JNJ) one way or another. As for Johnson & Johnson (NYSE:JNJ), this obsession with Boston Scientific (NYSE:BSX) might prove to be costly for them because of all the proceedings and what not. And should the case get overturned or if Johnson & Johnson (NYSE:JNJ) is tangled into some legal matter, there is a chance that it might lose money too.

Johnson & Johnson (NYSE:JNJ) still has a healthy case, after all it’s a genuine breach of contract.

Gilead (NASDAQ:GILD) has been down 4% on fears that their hepatitis c drug won’t compete effectively against Johnson & Johnson (NYSE:JNJ)

This successful U.S. regulators approved drug by Johnson & Johnson (NYSE:JNJ) is called Olysio. Its sales in the second quarter were strong and remained strong in the third quarter in which they were recorded at $796 million.

Things will soon become competitive for Olysio; according to Damien Conover, an analyst of Morningstar. He believes Olysio sales will dwindle after the approval of a new and more potent treatment pill by the name of Harvoni, which has been manufactured by Gilead Sciences Inc. (NASDAQ:GILD); the approval for Harvoni is expected to come this Friday. According to Conover’s estimates, Harvoni’s launch will cause a dip in Olysio’s sales by 50% in 2015.

Despite this upcoming approval Conover believed that Johnson & Johnson (NYSE:JNJ) had strong third quarter results in which sales for its drugs Zytiga (prostate cancer treatment), Xareltos (prevention for blood clots) and Olysio stayed strong. Conover believes that important drugs are selling well and there is a lot of competition for the big players, which is a healthy sign for pharmaceutical stocks.

Harvoni is expected to be an expensive treatment, which will cost $94,500. It is a combination of Gilead’s Sovaldi pill, which costs $84,000, and ledipasvir.

Johnson & Johnson (NYSE:JNJ)’s CFO Dominic Caruso hopes that the company will remain strong in pharmaceutical market and will experiment by combining Olysio with more advance treatment options. He further said that Johnson & Johnson (NYSE:JNJ) does not shy away from investing into this strong market.

According to the company’s quarterly reports drug sales of Johnson & Johnson (NYSE:JNJ) went up by 18% to reach $8.3 billion. However things weren’t this good for the company’s medical devices in the third quarter; their sales went down by 5.2% to reach $6.6 billion. The main reason for this decline in medical devices sales was the disposal of Ortho-Clinical Diagnostics cell of the company along with the recession in economy that caused a decline in surgical procedures. A few consumer products also saw a decline in sales by 0.6% to reach $3.6 billion; these products included Tylenol.

Other Highlights

• Johnson & Johnson (NYSE:JNJ)’s third quarter earnings were $4.75 billion ($1.66/share,), which were an improvement from last year’s $2.98 billion ($1.04/share).
• Per share earnings for Johnson & Johnson (NYSE:JNJ) were $1.50, which does not include special items. These figures are better than estimates of $1.45/share.
• Overall sales for the company jumped up by 5.1%, which is equal to $18.47 billion. This figure also beat estimates, which were $18.38 billion.
• Johnson & Johnson (NYSE:JNJ) per share earnings forecast for the full year is between $5.92 and $5.97 per share; these estimates are better than its July forecast that was between $5.85 and $5.92.

Johnson & Johnson (NYSE:JNJ) stock opened today at $100.53.

In the announcement, a spokesman for Alios Biopharma was quoted earlier as saying,

Alios BioPharma’s Chief Executive Officer, Lawrence M. Blatt expressed his joy in becoming a part of Johnson & Johnson (NYSE:JNJ)’s Janssen Pharmaceutical. He believes the company has a great history of introducing groundbreaking viral drugs into the market. Blatt believes that Alio’s efforts in targeting a variety of viral infections will blend well with Janssen’s efforts for finding innovative treatments for infections that are life threatening.

Alios are currently at an advanced stage in developing a treatment for infants suffering from respiratory syncytial virus (RSV), and it is important to note that this will be included in the deal. The treatment, known currently as AL-8716, is to be administered orally to the infants.

The deal opens up opportunities for Johnson & Johnson (NYSE:JNJ) to expand their explorations into treatment options for a number of viral infections as well as RSV via their Janssen Pharmaceutical unit. Comment on this was provided by the global head of R&D at the company, William N.Hait, who claimed that “RSV is the last of the major paediatric diseases with no available preventative therapy” while adding “AL-8176 complements our (Johnson & Johnson (NYSE:JNJ) existing early stage portfolio for RSV which aims to prevent and treat this disease.”

It is not believed that the purchase will be completed by the end of this quarter, though will almost certainly be settled by the end of the fourth quarter. It is believed that delays in the deal being concluded are due to scrutiny from executors of the Hart-Scott-Rodino Antitrust Improvements Act among other long standing customary closing conditions.

The acquisition is Johnson & Johnson (NYSE:JNJ)’s first of 2014 and the company moved into the third quarter holding $29.39 billion in cash and equivalents on its balance sheet. The company has 275 companies operating under its name across 60 countries including the US, and sells products in virtually all countries of the world. The company’s last significant acquisitions were the deal for Flexible Stenting Solutions Inc. in March 2013. They also concluded a divestiture deal for Ortho-Clinical Diagnostics business to Carlyle Group. It is believed that this later merger will be reflected positively by the markets that will see the potential in rolling out the RSV medicine.

Johnson & Johnson (NYSE:JNJ) opened today at a value of 106.50 and at 10:38 am EDT was trading at 106.80. The stock’s inst. Ownership is 67% whereas its range between 52 weeks has been between 85.50 and 108.77.